General
Preferred name
Cefradine
Synonyms
Sefril ()
Cephradine ()
cephradine ()
SQ-11436 ()
Cephradine monohydrate ()
Cephradine, Sefril, Anspor, Cephradin, Velosef ()
Anspor ()
SK&F D-39304 ()
Cephradine hydrate ()
SK-D-39304 ()
Cephradine, unspecified hydrate ()
Ecosporina ()
Velosef ()
SQ 11436 ()
SQ 22022 [DIHYDRATE] ()
Velosef '250' ()
Nicef ()
SQ-22022 ()
Cefradine hydrate ()
Cephradine anhydrous ()
NSC-756672 ()
Velosef '125' ()
Velosef '500' ()
P&D ID
PD009555
CAS
38821-53-3
75975-70-1
Tags
natural product
drug
available
Approved by
FDA
First approval
1974
Drug Status
approved
withdrawn
Drug indication
Bacterial infection
Antibacterial
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Cefradine is a cephalosporin antibacterial. (GtoPdb)
Compound Sets
21
Cayman Chemical Bioactives
26060
ChEMBL Approved Drugs
CHEMBL1604
ChEMBL Drugs
CHEMBL1604
Concise Guide to Pharmacology 2017/18
4830
Concise Guide to Pharmacology 2019/20
4830
Concise Guide to Pharmacology 2021/22
4830
Concise Guide to Pharmacology 2023/24
4830
Drug Repurposing Hub
DrugBank
DB01333
DrugBank Approved Drugs
DB01333
DrugCentral
576
DrugCentral Approved Drugs
576
DrugMAP
DMUNSWV
DrugMAP Approved Drugs
DMUNSWV
Enamine BioReference Compounds
Guide to Pharmacology
4830
MedChem Express Bioactive Compound Library
HY-B1156
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
cefradine
cephradine-monohydrate
Withdrawn 2.0
1022
External IDs
44
Properties
(calculated by RDKit )
Molecular Weight
349.11
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
0
cLogP
0.35
TPSA
112.73
Fraction CSP3
0.44
Chiral centers
3.0
Largest ring
6.0
QED
0.5
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Disease Area
infectious disease, otolaryngology
Indication
respiratory tract infections, otitis, skin infections, urinary tract infections, tonsillitis, pharyngitis, pneumonia
Target
CYP3A4
antibiotic
Bacterial
TOPK
Antibiotics,Bacterial
MOA
bacterial cell wall synthesis inhibitor
ATC
J01DB09
Therapeutic Class
Antibiotics
Pathway
Anti-infection
Cell Cycle/DNA Damage
Source data